Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (178 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 83 | 21% |
| 2020 | 0 | 28 | 25% |
| 2021 | 0 | 65 | 29% |
| 2022 | 1 | 52 | 33% |
| 2023 | 3 | 66 | 37% |
| 2024 | 2 | 129 | 39% |
| 2025 from claims | – | 208 170–246 | 40% |
| 2026 forecast | – | 249 197–315 | 35% |
| 2027 forecast | – | 278 209–371 | 34% |
| 2028 forecast | – | 311 224–434 | 34% |
| 2029 forecast | – | 348 241–505 | 33% |
| 2030 forecast | – | 389 260–585 | 33% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Hampshire; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 76% hospital outpatient, 24% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,426+10%/yr | +10%/yr | 0.7 | 39% | 2,520 in 2030+10%/yr |
| Pennsylvania | 15 | 1,377+8%/yr | +8%/yr | 0.9 | 44% | 1,810 in 2030+4.7%/yr |
| Massachusetts | 17 | 885+12%/yr | +12%/yr | 0.9 | 6% | 880 in 2030−0.1%/yr |
| New Jersey | 8 | 796+6.4%/yr | +6.4%/yr | 0.7 | 58% | 1,020 in 2030+4.2%/yr |
| Connecticut | 5 | 307+9.1%/yr | +9.1%/yr | 0.9 | 30% | 680 in 2030+14%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 34 | 2,067+2.3%/yr | +2.3%/yr | 8.81.2× | 67% | 3,130 in 2030+7.1%/yr |
| Spinal cord & DRG stimulation | 2 | 106+1%/yr | +1%/yr | 0.41.1× | 46% | 190 in 2030+11%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
Boston Scientific leads with 64% of company spending on these surgeons in 2025, +28 pts on 2024.
In 2025, 5 companies reported engagement with New Hampshire’s surgeons worth $12K in consulting, speaking, meals and travel tied to these products, about $5,830 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.